GoodRx offers Eli Lilly's new oral GLP-1 drug at $149 monthly
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
GoodRx Expands Access to Eli Lilly and Company’s New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide
April 9, 2026 7:30 AM EDTEligible self-pay consumers can access Foundayo starting at $149 per month through GoodRx
Brief Summary:
GoodRx is expanding access to the newly FDA-approved oral GLP-1 medication, Foundayo (orforglipron) Eligible self-pay consumers can access Foundayo starting at $149 per month through GoodRx GoodRx is also offering self-pay pricing for Zepbound® (tirzepatide) KwikPen® starting at $299 per month Foundayo and Zepbound KwikPen are available through GoodRxs nationwide pharmacy network GoodRx is helping pharmaceutical manufacturers deliver consumer-direct pricing at scale from day oneSANTA MONICA,... More
